Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

Abstract In this phase I dose-escalation trial, we assess the maximum tolerated dose (MTD) of Bermekimab in combination with Nanoliposomal Irinotecan (Nal-Iri) and 5-Fluorouracil/Folinic Acid (5-FU/FA). Secondarily, we investigate effects on weight, lean body mass, quality-of-life, the gut microbiom...

Full description

Bibliographic Details
Main Authors: Jun Gong, Shant Thomassian, Sungjin Kim, Gillian Gresham, Natalie Moshayedi, Jason Y. Ye, Julianne C. Yang, Jonathan P. Jacobs, Simon Lo, Nick Nissen, Srinivas Gaddam, Mourad Tighiouart, Arsen Osipov, Andrew Hendifar
Format: Article
Language:English
Published: Nature Portfolio 2022-09-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-19401-3

Internet

https://doi.org/10.1038/s41598-022-19401-3

Similar Items